T he ability to utilize cytokines clinically relies on identifying the specific pathophysiologic functions of individual cytokines in the host's defenses. With the availability of pharmacological quantities of recombinant cytokines, suf~dent to be evaluated in animal modds, it was originally anticipated that individual cytokines could be ascribed specific biologic activities. Indeed, initial studies documented that many inflammatory processes could be reproduced by systemic administration of rib1 or of ffNF-c~, establishing these two cytokines as major inflammatory mediators (1, 2) . Subsequent studies, however, suggested that many of the actions of II:1 or TNF, induding stimulation of production of acute phase proteins by hepatocytes (3, 4) , stimulation of the hypothalamic-pituitary-adrenal axis (5-7), or hematopoietin 1 effects (8, 9) , can be mimicked by I1:6 (10) (11) (12) (13) (14) .
Because I1:1 and TNF induce I1:6 (15, 16) , the possibility that these relatively toxic cytokines can be replaced by the much less toxic IL-6 presents an obvious clinical advantage. To examine this possibility, we evaluated the contribution of II:6 in several I1:1-and TNF-mediated activities, by testing Antibodies. Rat mAb to mouse rib6 (MP5 20F3) was prepared using semi-purified Cos-7 mouse II.,6 as an immunogen, as previously described (18) . The isotype control, rat mAb to B-gahctosidase (GLl13) was used. A rat monoclonal IgG1, anti-ILl receptor antibody (35F5) was previously described (19) . Chromatographically purified rat IgG (Sigma Chemical Co., St. Louis, MO) was used as an additional control. The antibodies and recombinant cytokines were diluted in pyrogen-free saline on the day of injection. Antibodies were given intraperitoneally 6-20 h before intraperitoneal injection of the cytokines.
Irradiation. Mice were randomized, placed in plexiglass containers, and were given whole-body irradiation at 40 cGy/min midline tissue dose, by bilaterally positioned 6~ elements. The radiation field was uniform within _+2%. The number of surviving mice was recorded daily for 30 d.
Immunoenzymetric Assay for IL.6 Determinations in the Serum.
Serum samples obtained at 2-4 h after cytokine injections were assayed for IL-6 using a two-site sandwich immunoassay as described (18) . The threshold sensitivity of this assay was 50 pg/ml.
Measurements of ACTH in Plasma.
ACTH was assayed in plasma from decapitated mice using an 1~I RIA kit (INCSTAR Corp., Stillwater, MN) as previously described (17) . The ACTH antibody used in this assay is derived from rabbits immunized against human ACTH1-24, a region identical in human and routine ACTH. The threshold sensitivity of this assay was 8 pg/ml.
Glucose Determination. Levels of glucose in serum samples were measured using glucose oxidase reagent kit (KODAK Ektachem Clinical Chemistry Slide) as described elsewhere (20) . In this assay, hydrogen peroxide is detected based on its oxidant activity in a peroxidase-catalyzed oxidative-coupling reaction in the presence of chromogen to form a dye. The intensity of the dye is measured at 540 nm. The Kodak Ektachem-700 Analyzer was calibrated before each assay.
Statistical Analysis. Statistical evaluation of the results was carried out using X a analysis and analysis of variance followed by Fisher protected least significant difference test.
Results
The Role of lL.6 in Innate Radioresistance. Previous work has indicated that administration of anti-IL-1R or anti-TNF antibody results in increased mortality of irradiated mice (21) . To examine whether endogenously produced Ib6 contributes to innate radioresistance, anti-Ib6 antibody was given to normal, untreated mice before irradiation. Such treatment greatly enhanced the incidence of mortality, from 35 to 80% (Fig. 1) . Thus, endogenously produced IL-6 clearly contributes to the survival of mice recovering from radiation injury.
Comparison of lL.1 and TNF for Induction of lL.6.
We have previously shown that pretreatment with I b l or TNF results in enhanced survival of lethaUy irradiated mice. Since IL-1 and TNF are known to induce IL-6, we next sought to determine the relative contribution of IL-6 in TNF-and in Ib 1-treated mice. We first determined the levels of Ib6 in cir- (Table 1) . Consistent with previous findings (15) , detectable serum Ib6 levels appeared even after doses as low as 10 ng of IL-1, but microgram doses of TNF were required to induce measurable circulating Ib6. Consequently, a dose of 600/~g/mouse of anti-Ib6 antibody neutralized serum II.-6 in mice given 5 /~g/mouse of TNF, but this dose was insufficient to completely block serum IL-6 in mice given 300 ng of II.-1 (Table  1) . Therefore, in subsequent studies of the contribution of CD2FI mice were given saline injections, anti-IL-6 Ab (600/~g/mouse), or control Ab (GLl13, 600/~g/mouse), followed by cytokine treatment 16 h later, and were bled at 2 and 4 h after cytokine administration. Sera from pools of three mice/group were assessed for IL-6. The levels of IL-6 are shown for 2 h after IL-1 injections and 4 h after TNF injections (since these were the optimal levels, with the exception, however, for anti-IL-6 and 300 ng of IL-1 where the results of two experiments of 4 h of bleeding and one experiment of 2 h of bleeding were combined). The results are means of two to four experiments (individuals values varied within ~-20%). Ib6 in induction of protection from radiation lethality, hypoglycemia, and ACTH release, doses of I1.1 and TNF were used that could be neutralized by the anti-I1.6 antibody.
The Role of lL6 in IL-1-and TNF-enhanced Survival from Lethal
Irradiation. Both I1-1 and TNF promote survival from radiation lethality (22, 23) . To assess the role of I1.6 in mediating the recuperative effects of these two cytokines, mice were given anti-I1.6 antibody 6-20 h before administration of I1.1 (100 ng) or TNF (5/~g). The results (Fig. 2, A and  B) indicate that anti-I1.6 antibody can completely block both IL-1-and TNF-enhanced survival from lethal irradiation.
The Role of lL6 in 11.,1-and TNF-induced Hypoglycemia.
As previously demonstrated, both 11.1 and TNF induce, within 2-4 h, hypoglycemia in mice (24) . Ibl, however, is much more potent than TNF in inducing hypoglycemia, since as little as 20 ng of I1.1 induced hypoglycemia, whereas >5/~g of TNF was required to induce a similar decrease in blood glucose levels. Anti-Ib6 antibody did not change the magnitude of I1.1-induced hypoglycemia (Fig. 3 A) . In contrast, the same dose of anti-Ib6 resulted in a significant reversal of TNF-induced hypoglycemia (Fig. 3 B) .
ILI/IL6 Interaction in ACTH Induction. Our previous work determined that I1.-1 and II.-6 interact synergistically to induce circulating ACTH (17) . To assess the contribution of II.-6 in Ibl-induced ACTH release, mice were given anti-II.-6 antibody before receiving II.-1. As shown in Fig. 4 , anti-Ib6 antibody blocked the ACTH response to 1I_,1. Since no consistent elevation ofphsma ACTH was detected in TNFtreated mice, similar experiments using anti-Ib6 antibody were not conducted in TNF-treated mice.
Discussion
The availability of neutralizing antibody to cytokines allows the assessment of the contribution of individual cytokines and their interaction in host defenses in vivo. For example, our previous studies demonstrated that administration of anti-IL-1R and anti-TNF antibody to normal mice caused greater mortality upon exposure of these mice to lethal radiation (21) . Moreover, anti-II.-1R antibody not only blocked ILl-induced, but also TNF-induced protection from lethal irradiation. Conversely, anti-TNF antibody also reduced II.-1-induced protection from radiation death, suggesting that these two cytokines induce one another in vitro and in vivo (25) (26) (27) (28) , and that their interaction is necessary for enhanced survival from lethal irradiation.
11.6 not only fails to induce 11,1 or TNF, but actually has been reported to suppress their production (29, 30) . Thus, as we have previously observed, administration of II.-6 alone before irradiation would not be expected to lead to enhanced survival and would actually reduce survival from lethal irradiation (15) . Despite this, injection of anti-I1,6 antibody in this study results in increased mortality of irradiated, normal mice as well as irradiated TNF-or I1,1-treated mice. These observations suggest that II.-6 participates in both innate as well as II..1-and TNF-induced resistance to radiation lethality.
The failure of IL-6 by itself to improve radiation survival indicates that the activity of I1,6 only becomes manifest in the course of interaction with other cytokines. This hypothesis is supported by our earlier report that I1,6 given together with suboptimal doses of Ibl resulted in synergistically enhanced survival from lethal irradiation (15) . Since radiation itself induces the production of endogenous II.-1 (31) (32) (33) and TNF (34, 35) , their presence would be expected to result in endogenous production of Ib6. Consequently, the interaction of all three cytokines, i.e., IL-1, TNF, and IL-6, would contribute to innate resistance of normal mice to radiation lethality.
When given individually, II.-1 and TNF induce significant protection from radiation-induced lethality and induce hypoglycemia. One possible explanation for the observed lower potency of TNF in both of these biologic responses may be related to its much lower capacity to induce Ib6 (Table 1) . Even 20 ng dose of II.-1 induced higher levels of II.,6 than 5/~g of TNF. Our results indicate that 600/~g of anti-Ib6 antibody blocked radioprotection and ACTH induction with 100 ng I1-1, whereas the hypoglycemia induced with 20 ng II;1 was not significantly affected by this antibody. In contrast, TNF-induced hypoglycemia can be reduced by anti-II:6 antibody. This suggests that the mechanisms of induction of hypoglycemia by these two cytokines differ. Alternatively, induction of II.-6 or distribution of antibody may vary in different tissues. Our previous work, showing a synergistic interaction of IL-1 and TNF in induction of hypoglycemia (24) , supports the first of these two hypotheses.
The ability to block Ibl-induced release of ACTH with anti-I1,6 antibody further extends our previous findings, which showed that Ibl and Ib6 synergize to induce ACTH (17) . In that study, doses of 10/~g of II.-6 induced only minimal changes in plasma ACTH, whereas ILl alone induced ACTH within 2 h (a time interval also necessary for IL-1 induction of IL-6) (15). The combination of Ilo-1 and II.~6 induced optimal levels of ACTH within 30 min. Thus, together with our present results, these observations strongly support the hypothesis that the simultaneous presence of both IL-1 and Ib6 is necessary for release of ACTH in vivo. Our attempts to observe similar elevation of plasma ACTH after administration of 5 #g TNF to C3H/HeN mice were unsuccessful (Perlstein and Neta, unpublished results). Thus, TNF may not induce levels of IL6 sufficient to induce ACTH. A previous report, which showed that rats given IIr alone have elevated plasma ACTH (13), may be explained either by a lower requirement for this interaction in rats or, alternatively, by the possible presence of sufficient endogenous levels of Ibl in this species.
In conclusion, these results serve to reconcile the apparently conflicting observations by many laboratories concerning the relative importance of the contributions of Ibl, TNF, and I1,6 to a variety of pathophysiological reactions. The interdependence and synergistic interactions of these three cytokines are apparently mandatory for many of their biological effects.
